Center for Quality Aging, Vanderbilt University Medical Center, Nashville, Tennessee.
Geriatric Research Education and Clinical Center, Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee.
JAMA Intern Med. 2023 Mar 1;183(3):223-231. doi: 10.1001/jamainternmed.2022.6545.
Deprescribing is a promising approach to addressing the burden of polypharmacy. Few studies have initiated comprehensive deprescribing in the hospital setting among older patients requiring ongoing care in a postacute care (PAC) facility.
To evaluate the efficacy of a patient-centered deprescribing intervention among hospitalized older adults transitioning or being discharged to a PAC facility.
DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial of the Shed-MEDS (Best Possible Medication History, Evaluate, Deprescribing Recommendations, and Synthesis) deprescribing intervention was conducted between March 2016 and October 2020. Patients who were admitted to an academic medical center and discharged to 1 of 22 PAC facilities affiliated with the medical center were recruited. Patients who were 50 years or older and had 5 or more prehospital medications were enrolled and randomized 1:1 to the intervention group or control group. Patients who were non-English speaking, were unhoused, were long-stay residents of nursing homes, or had less than 6 months of life expectancy were excluded. An intention-to-treat approach was used.
The intervention group received the Shed-MEDS intervention, which consisted of a pharmacist- or nurse practitioner-led comprehensive medication review, patient or surrogate-approved deprescribing recommendations, and deprescribing actions that were initiated in the hospital and continued throughout the PAC facility stay. The control group received usual care at the hospital and PAC facility.
The primary outcome was the total medication count at hospital discharge and PAC facility discharge, with follow-up assessments during the 90-day period after PAC facility discharge. Secondary outcomes included the total number of potentially inappropriate medications at each time point, the Drug Burden Index, and adverse events.
A total of 372 participants (mean [SD] age, 76.2 [10.7] years; 229 females [62%]) were randomized to the intervention or control groups. Of these participants, 284 were included in the intention-to-treat analysis (142 in the intervention group and 142 in the control group). Overall, there was a statistically significant treatment effect, with patients in the intervention group taking a mean of 14% fewer medications at PAC facility discharge (mean ratio, 0.86; 95% CI, 0.80-0.93; P < .001) and 15% fewer medications at the 90-day follow-up (mean ratio, 0.85; 95% CI, 0.78-0.92; P < .001) compared with the control group. The intervention additionally reduced patient exposure to potentially inappropriate medications and Drug Burden Index. Adverse drug event rates were similar between the intervention and control groups (hazard ratio, 0.83; 95% CI, 0.52-1.30).
Results of this trial showed that the Shed-MEDS patient-centered deprescribing intervention was safe and effective in reducing the total medication burden at PAC facility discharge and 90 days after discharge. Future studies are needed to examine the effect of this intervention on patient-reported and long-term clinical outcomes.
ClinicalTrials.gov Identifier: NCT02979353.
减少用药是解决多种药物治疗负担的一种很有前途的方法。很少有研究在需要在康复护理 (PAC) 机构继续护理的老年患者的医院环境中全面开展减少用药。
评估以患者为中心的减少用药干预措施在从医院过渡或出院到 PAC 机构的老年患者中的疗效。
设计、地点和参与者:这项 Shed-MEDS(最佳药物史、评估、减少用药建议和综合)减少用药干预的随机临床试验于 2016 年 3 月至 2020 年 10 月进行。招募了入住学术医疗中心并出院到医疗中心附属的 22 个 PAC 机构之一的患者。纳入年龄在 50 岁及以上且有 5 种或 5 种以上院前药物的患者,并按 1:1 随机分为干预组或对照组。排除非英语患者、无家可归者、长期居住在养老院的居民或预期寿命不足 6 个月的患者。采用意向治疗方法。
干预组接受 Shed-MEDS 干预,包括药剂师或执业护士主导的全面药物审查、患者或代理人批准的减少用药建议,以及在医院开始并在 PAC 机构住院期间继续进行的减少用药行动。对照组在医院和 PAC 机构接受常规护理。
主要结局是医院出院和 PAC 机构出院时的总用药量,并在 PAC 机构出院后 90 天内进行随访评估。次要结局包括每个时间点的潜在不适当药物总数、药物负担指数和不良事件。
共纳入 372 名参与者(平均[标准差]年龄 76.2[10.7]岁;229 名女性[62%]),随机分为干预组或对照组。这些参与者中,284 名纳入意向治疗分析(干预组 142 名,对照组 142 名)。总体而言,治疗效果具有统计学意义,与对照组相比,干预组患者在 PAC 机构出院时服用的药物平均减少 14%(平均比值,0.86;95%CI,0.80-0.93;P<0.001),90 天随访时服用的药物减少 15%(平均比值,0.85;95%CI,0.78-0.92;P<0.001)。该干预措施还减少了患者接触潜在不适当药物和药物负担指数的情况。干预组和对照组的药物不良事件发生率相似(危害比,0.83;95%CI,0.52-1.30)。
这项试验的结果表明,Shed-MEDS 以患者为中心的减少用药干预措施在降低 PAC 机构出院时和出院后 90 天的总用药负担方面是安全有效的。未来需要研究该干预措施对患者报告和长期临床结局的影响。
ClinicalTrials.gov 标识符:NCT02979353。